Cargando…

FIB‑4 index and NAFLD fibrosis score are useful indicators for screening high‑risk groups of non‑viral hepatocellular carcinoma

Non-viral hepatocellular carcinoma (HCC) tends to appear in non-cirrhotic livers, rendering it difficult to screen for a high-risk group. The present study aimed to identify the most suitable indicator for screening high-risk groups of non-viral HCC. A total of 190 patients with non-viral HCC, inclu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imai, Kenji, Takai, Koji, Unome, Shinji, Miwa, Takao, Hanai, Tatsunori, Suetsugu, Atsushi, Shimizu, Masahito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502796/ https://www.ncbi.nlm.nih.gov/pubmed/37719044 http://dx.doi.org/10.3892/mco.2023.2676

Ejemplares similares

Lenvatinib or Sorafenib Treatment Causing a Decrease in Skeletal Muscle Mass, an Independent Prognostic Factor in Hepatocellular Carcinoma: A Survival Analysis Using Time-Varying Covariates
por: Imai, Kenji, et al.
Publicado: (2023)

Higher Accumulation of Visceral Adipose Tissue Is an Independent Risk Factor for Hepatocellular Carcinoma among Viral Hepatitis Patients with Non-Cirrhotic Livers
por: Imai, Kenji, et al.
Publicado: (2021)

Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma
por: Unome, Shinji, et al.
Publicado: (2022)

Rapid Depletion of Subcutaneous Adipose Tissue during Sorafenib Treatment Predicts Poor Survival in Patients with Hepatocellular Carcinoma
por: Imai, Kenji, et al.
Publicado: (2020)

Rapid Depletions of Subcutaneous Fat Mass and Skeletal Muscle Mass Predict Worse Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Imai, Kenji, et al.
Publicado: (2019)

Increased Visceral Adipose Tissue and Hyperinsulinemia Raise the Risk for Recurrence of Non-B Non-C Hepatocellular Carcinoma after Curative Treatment
por: Imai, Kenji, et al.
Publicado: (2021)

Effect of Selenium Deficiency on the Development of Overt Hepatic Encephalopathy in Patients with Chronic Liver Disease
por: Nakahata, Yuki, et al.
Publicado: (2023)

Prevalence, association, and prognostic significance of polypharmacy and sarcopenia in patients with liver cirrhosis
por: Hanai, Tatsunori, et al.
Publicado: (2023)

Homeostatic Model Assessment of Insulin Resistance for Predicting the Recurrence of Hepatocellular Carcinoma after Curative Treatment
por: Imai, Kenji, et al.
Publicado: (2019)

Sustained virological response by direct-acting antivirals reduces the recurrence risk of hepatitis C-related hepatocellular carcinoma after curative treatment
por: Imai, Kenji, et al.
Publicado: (2020)

Usefulness of the Trabecular Bone Score in Assessing the Risk of Vertebral Fractures in Patients with Cirrhosis
por: Ogiso, Yui, et al.
Publicado: (2022)

Recurrent hepatogastric fistula during lenvatinib therapy for advanced hepatocellular carcinoma managed by over-the-scope clip closure: a case report
por: Miwa, Takao, et al.
Publicado: (2021)

Late Evening Snack with Branched-Chain Amino Acids Supplementation Improves Survival in Patients with Cirrhosis
por: Hanai, Tatsunori, et al.
Publicado: (2020)

Sarcopenia Impairs Prognosis of Patients with Hepatocellular Carcinoma: The Role of Liver Functional Reserve and Tumor-Related Factors in Loss of Skeletal Muscle Volume
por: Imai, Kenji, et al.
Publicado: (2017)

Usefulness of the Stroop Test in Diagnosing Minimal Hepatic Encephalopathy and Predicting Overt Hepatic Encephalopathy
por: Hanai, Tatsunori, et al.
Publicado: (2021)

A simple covert hepatic encephalopathy screening model based on blood biochemical parameters in patients with cirrhosis
por: Miwa, Takao, et al.
Publicado: (2022)

Association between Body Composition and the Risk of Portopulmonary Hypertension Assessed by Computed Tomography in Patients with Liver Cirrhosis
por: Miwa, Takao, et al.
Publicado: (2023)

Increased visceral fat volume raises the risk for recurrence of hepatocellular carcinoma after curative treatment
por: Imai, Kenji, et al.
Publicado: (2018)

Skeletal Muscle Depletion Predicts the Prognosis of Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Imai, Kenji, et al.
Publicado: (2015)

Development of diffuse large B-cell lymphoma after sofosbuvir-ledipasvir treatment for chronic hepatitis C: A case report and literature review
por: Sakai, Hiroyasu, et al.
Publicado: (2020)

Usefulness of Carnitine Supplementation for the Complications of Liver Cirrhosis
por: Hanai, Tatsunori, et al.
Publicado: (2020)

Effects of Rifaximin on Circulating Albumin Structures and Serum Ammonia Levels in Patients with Liver Cirrhosis: A Preliminary Study
por: Miwa, Takao, et al.
Publicado: (2022)

Prognostic accuracy of FIB‐4, NAFLD fibrosis score and APRI for NAFLD‐related events: A systematic review
por: Lee, Jenny, et al.
Publicado: (2021)

Impact of Serum Chemerin Levels on Liver Functional Reserves and Platelet Counts in Patients with Hepatocellular Carcinoma
por: Imai, Kenji, et al.
Publicado: (2014)

Mac-2-binding protein glycosylation isomer is useful to predict muscle cramps in patients with chronic liver disease
por: Miwa, Takao, et al.
Publicado: (2022)

FIB-4 is closer to FibroScan screen results to detecting advanced liver fibrosis and maybe facilitates NAFLD warning
por: Ding, Yuping, et al.
Publicado: (2023)

Ability of a Combined FIB4/miRNA181a Score to Predict Significant Liver Fibrosis in NAFLD Patients
por: Lima, Rodrigo Vieira Costa, et al.
Publicado: (2021)

Idiopathic Ileocolonic Varices Coexisting with a Colon Polyp Treated Successfully by Endoscopy: A Case Report and Literature Review
por: Miwa, Takao, et al.
Publicado: (2019)

Acyclic retinoid in chemoprevention of hepatocellular carcinoma: Targeting phosphorylated retinoid X receptor-α for prevention of liver carcinogenesis
por: Shimizu, Masahito, et al.
Publicado: (2012)

Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4
por: John, Katharina, et al.
Publicado: (2022)

The FIB-4 Index Predicts the Development of Liver-Related Events, Extrahepatic Cancers, and Coronary Vascular Disease in Patients with NAFLD
por: Kamada, Yoshihiro, et al.
Publicado: (2022)

Evaluation of NAFLD fibrosis, FIB-4 and APRI score in diabetic patients receiving exenatide treatment for non-alcoholic fatty liver disease
por: Unsal, İlknur Ozturk, et al.
Publicado: (2022)

Can FIB4 and NAFLD fibrosis scores help endocrinologists refer patients with non-alcoholic fat liver disease to a hepatologist?
por: Nones, Rodrigo Bremer, et al.
Publicado: (2017)

Aspartate transaminase to platelet ratio index (APRI) but not FIB-5 or FIB-4 is accurate in ruling out significant fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) in an urban slum-dwelling population
por: Kolhe, Kailash Marotrao, et al.
Publicado: (2019)

Increased levels of serum leptin are a risk factor for the recurrence of stage I/II hepatocellular carcinoma after curative treatment
por: Watanabe, Naoki, et al.
Publicado: (2011)

Usefulness of health checkup for screening metabolic dysfunction-associated fatty liver disease and alcohol-related liver disease in Japanese male young adults
por: Tajirika, Satoko, et al.
Publicado: (2023)

FIB-5 versus FIB-4 index for assessment of hepatic fibrosis in chronic hepatitis B affected patients
por: Metwally, Khaled, et al.
Publicado: (2020)

Accuracy of Ultrasound Elastography and Fibrosis-4 Index (FIB-4) in Ruling Out Cirrhosis in Obese Non-Alcoholic Fatty Liver Disease (NAFLD) Patients
por: Damjanovska, Sofi, et al.
Publicado: (2022)

APRI and FIB-4 indices as diagnostic noninvasive scores for prediction of severe fibrosis in patients with biliary atresia
por: Nagi, Salma Abdel Megeed, et al.
Publicado: (2023)

FIB nanostructures
por: Wang, Zhiming M
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_touscjj06dbud5ad5246eh4an3